Trisol Medical Announces Positive Results from U.S. Early Feasibility Study of Its Transcatheter Tricuspid Valve Replacement System

Results demonstrate a favorable safety profile and functional improvements in patients with severe tricuspid regurgitation including patients with reduced right ventricle function

YOKNEAM, Israel, Jan. 21, 2026 /PRNewswire/ -- Trisol Medical, a clinical-stage medical device company developing a transcatheter tricuspid valve replacement system, today announced positive results from its FDA-approved U.S. Early Feasibility Study evaluating the Trisol Transcatheter Tricuspid Valve in patients with severe to torrential tricuspid regurgitation.

 

 

Trisol's Transcatheter Tricuspid Valve Replacement (TTVR) system is designed to treat severe to torrential tricuspid regurgitation (TR), a condition in which the tricuspid valve fails to close properly, allowing blood to flow backward from the right ventricle to the right atrium. Patients with this condition often have limited treatment options.

To date, 22 patients with severe to torrential TR who were considered high risk for conventional surgery have been treated at leading U.S. centers, including Piedmont Heart Institute, Vanderbilt University Medical Center, University of Virginia Health System, Columbia University Medical Center, and Cedars-Sinai Medical Center, using a trans-jugular (TJ) access approach. Enrollment in the TJ cohort is now complete, and the study is proceeding with continued enrollment using Trisol's newly developed trans-femoral access route.

Key Study Results

• Safety: Less than 5% need for permanent pacemaker at 30-day follow-up. 
• Effectiveness: Considerable reduction in TR following implantation. 
• Functional outcomes: At 30-day and 12-month follow-up, notable improvements were observed in quality of life (KCCQ), heart failure symptoms (NYHA class), 6-minute walk distance, right ventricular function, and cardiac output. 
• Technical performance: Successful deployment of the device and no incidents of migration.

Importantly, these encouraging results include patients with reduced right ventricular function, a large, high-risk subgroup associated with poorer outcomes and underserved by existing and emerging treatment approaches. Early clinical experience reported to date across emerging therapies highlights a persistent unmet need in this patient population, suggesting the Trisol valve could help address this critical gap.

Dr. Pradeep Yadav commented: "Trisol brings several novel features from ease of use to recapturable anchors, broad size range, lower pacemaker rate and performance in dysfunctional right ventricles. We are very excited to investigate the next phase with its transfemoral delivery system and pivotal trial."

"We are thrilled by these positive outcomes, which further validate the potential of our best-in-class technology to improve care for patients with severe TR. I would like to thank our clinical investigators and the entire clinical teams for their dedication and outstanding patient care," said Ron Davidson, CEO of Trisol Medical.

Dr. Shimon Eckhouse, Chairman of Trisol, added: "Millions of Americans suffer from TR, and despite recent advances, effective treatment options remain limited for patients with severe TR. The Trisol valve was developed to address this significant unmet need and has the potential to redefine the standard of care."

About Trisol Medical

Trisol Medical Ltd. is a clinical-stage medical device company specializing in the development of a novel TTVR. Founded within the Alon MedTech Ventures incubator, Trisol is dedicated to advancing minimally invasive heart valve therapies that offer safer alternatives to traditional surgical procedures. For further details, please visit: www.trisol-medical.com.

Media contact:
Ron Davidson
CEO
rond@trisol-medical.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Trisol Medical Announces Positive Results from U.S. Early Feasibility Study of Its Transcatheter Tricuspid Valve Replacement System

SEOUL, South Korea, April 3, 2026 /PRNewswire/ -- The 2026 Asia Design Prize ceremony took place recently in Seoul, South Korea. MINISO took home three awards for its original designs, standing out among more than 1,500 submissions from 31 countries and regions. Flip Mirror earned a Gold Winner award, while Lumion Brush and Light Forest received Winner recognition, pointing to MINISO's growing in-house design and R&D capabilities.

Asia Design Prize is one of Asia's most influential international design awards. Renowned for its rigorous, impartial jury process and global perspective, the competition spotlights work that reflects where design is heading and helps bring those ideas and practice to a wider audience. It has become a visible platform connecting Asian design talent with the international stage.

These three winning products each address distinct everyday scenarios, combining sharp user-centric insight with structural innovation to make daily routines more intuitive.

Flip Mirror, the Gold Winner, is a hidden-storage compact mirror. With a flip mechanism, it tucks small items behind the mirror, blending storage and use in a way that feels seamless—even on a crowded desk. MINISO Seoul Design Center noted, "We wanted to turn everyday desktop organization into something simple, intuitive, and meaningful. Flip Mirror doesn't just keep your space tidy—it turns the act of flipping into a small, satisfying ritual."

Light Forest, an ambient mood light, draws inspiration from the silhouette of a forest. Its soft silicone shade conceals a squeeze sensor—users turn the light on and off with a gentle pinch, replacing traditional controls with a more tactile and playful interaction.

Lumion Brush, a portable scalp massager, focuses on personal care. It combines gentle vibration with ionic care, while its ergonomic, lightweight design makes it easy to use anywhere—at home or on the go—turning daily scalp care into something more efficient and effortless.

In recent years, MINISO has stepped up its focus on creative design as it expands globally. The company was an early advocate of "interest-driven consumption," and continues to push product innovation through a dual-engine approach— top-tier licensed IP collaborations and proprietary IP development—empowered by its design and technology capabilities. MINISO is advancing the development of four design centers in China, South Korea, Japan, and the United States, helping to build a global design network that continues to strengthen its original R&D capabilities. Winning multiple honor at Asia Design Prize further validates MINISO's sustained investment in its original design system. Looking ahead, MINISO will keep design at its core, bringing consumers products that are both inventive and genuinely useful.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

MINISO Secures Three Wins at the Asia Design Prize for Its Original Designs

MINISO Secures Three Wins at the Asia Design Prize for Its Original Designs

MINISO Secures Three Wins at the Asia Design Prize for Its Original Designs

MINISO Secures Three Wins at the Asia Design Prize for Its Original Designs